Aderans Co., Ltd.
Signed an exclusive license agreement for hair regeneration
intellectual property rights with Stemson Inc. (USA), which conducts hair growth research using iPS cells.
……
Aderans Co., Ltd. (Headquarters: Shinagawa-ku, Tokyo; Representative Director and Group CEO Yoshihiro Tsumura), which operates a global hair, beauty, and health wellness business, is developing hair regeneration that utilizes the regenerative power of iPS cells (induced pluripotent stem cells). On February 22nd (Thursday), we concluded a licensing agreement with Stemson Therapeutics, Inc. (Headquarters: San Diego, California, USA; CEO: Jeff Hamilton), which conducts research, for the intellectual property rights of hair regeneration through cell culture. We have concluded the agreement. This is the first time that Aderans has entered into a license agreement for intellectual property rights related to hair
restoration.
In hair regeneration research, most third-party research institutions in the United States and Japan are in the phase 1 safety testing stage. As far as we and Stemson are aware, there is currently no hair loss treatment that can grow new hair follicles, and various companies are proceeding with hair regeneration research, but Aderans Research, a group company of Aderans,・Since its establishment in 2002, the Institute (Headquarters: Atlanta, Georgia, USA; hereinafter referred to as ARI) has been conducting research on hair regeneration using cell culture, and in 2008, it took a step forward by conducting a phase 2 clinical trial to examine the effectiveness, etc. I was working on it. Since 2018, Stemson has been conducting unique hair regeneration research that utilizes the regenerative power of iPS cells. Aderans has entered into an exclusive worldwide license agreement to utilize ARI’s unique cell culture-based hair regeneration research in the development and commercialization of Stemson’s hair regeneration treatments.
Through this agreement, Stemson will be able to resume implementation of ARI’s “Cell Therapy Hair Regeneration Program,” which was being undertaken as a Phase 2 clinical trial, and will be able to integrate it into the existing hair loss cell therapy development pipeline. Through cooperation between our company and Stemson, we will move forward with the development and commercialization of hair
regeneration treatments for hair loss patients and many people who desire hair regeneration.
[Image 1: https://prtimes.jp/i/10292/864/resize/d10292-864-07db1f2ee2f5f8b628c0-0.jpg&s3=10292-864-742d991a7355e8a664a5bad1c1fdff17-780×632.jpg] From left) Dr. Ken Wasinich of Bosley, Matt Pozard, Executive Chairman of Stemson, Yoshihiro Tsumura, Group CEO of our company, and Jeff Hamilton, CEO of Stemson.
■Comment from Stemson CEO Jeff Hamilton
[Image 2: https://prtimes.jp/i/10292/864/resize/d10292-864-c60f49f176e0caebde54-0.jpg&s3=10292-864-be6a062105499e08965125b53dfaf30c-305×132.jpg] The addition of ARI’s technology and know-how and Phase 2 clinical stage development program to Stemson’s portfolio will enable the company to expand its pursuit of multiple cell therapy product concepts for a wide range of hair loss conditions. Early results from ARI’s pioneering research show the field the potential for
long-lasting hair regeneration by restoring functioning hair follicle cells and tissue. We hope to combine that research with our hair follicle cell and tissue engineering capabilities in the field of hair regeneration to create truly breakthrough products for hair loss patients.
■Comment from Yoshihiro Tsumura, Representative Director and Group CEO of Aderans Co., Ltd.
[Image 3: https://prtimes.jp/i/10292/864/resize/d10292-864-0c4ff454e4a51b63982d-0.png&s3=10292-864-a3757cf25487845fa4400dcb820ccb33-287×54.png ]
Since our founding in 1968, Aderans has been working on developing solutions for thinning hair. We are collaborating with Stemson on hair regeneration cell therapy research technology so that we can provide advanced solutions to people around the world. Working with Stemson’s team will further advance the company’s development efforts and expand the Bosley Clinic
We look forward to supporting your commercialization through our global network. ■Comment from Bosley Dr. Ken Wasinich
[Image 4: https://prtimes.jp/i/10292/864/resize/d10292-864-c6d13c67657706cc8aa2-0.png&s3=10292-864-d15e74cc9797e536228309057be7c708-304×66.png ]
Our pioneering work at ARI in developing the first-ever cell therapy solution for hair loss has yielded extremely promising results in clinical trials for the treatment of early androgenic alopecia in men. We have advanced expertise in hair follicle cell and tissue
engineering to successfully develop and commercialize this amazing hair regeneration solution.
We believe Stemson is ideally positioned.
■About Aderans Research Institute (ARI)
ARI is a group company of our company that was established in 2002 for the purpose of researching hair regeneration through cell culture. In the UK safety trial (Phase 1) of hair regeneration using cell culture, a certain level of efficacy was observed in 10 of the 33 subjects who received injections of cultured cells. Subsequently, the safety of cell therapy was ensured by improving the culture medium, and the safety of cell therapy, which involves culturing the subject’s scalp cells and returning them to the patient, was evaluated by a
third-party organization, and the product was approved by the U.S. FDA and introduced into the U.S. We have started Phase 2.
Subsequently, a Phase 2 clinical trial was conducted in the United States on approximately 450 human patients to treat early androgenic alopecia in men. Initial clinical data suggests that a single administration of functioning hair follicle cells to targeted scalp areas can safely produce hair growth without side effects and provide long-lasting results.
-Company Profile-
Company name: Aderans Research Institute
Established: 2002
Business content: Hair regeneration research using cell culture ■About Stemson Therapeutics
Stemson Therapeutics was established in 2018 with the mission of treating hair loss by utilizing the regenerative power of iPS cells (induced pluripotent stem cells), and conducts research and
development on cell therapy at the preclinical stage. going. We use iPS cells to regenerate the cells needed to grow damaged or depleted hair in patients suffering from hair loss. Hair follicle cells derived from iPS cells are used to grow new hair follicles, stimulating the growth of new hair to treat people suffering from various types of hair loss. To our knowledge, there are currently no treatments that can grow new hair follicles.
Our world-class team of scientists, advisors, and collaborators is passionate about bringing science-based, clinically tested hair loss treatments to the millions of hair loss patients seeking treatment. Masu.
-Company Profile-
Company name: Stemson Therapeutics
Address: 3550 General Atomics Ct, Building2, Suite131, San Diego, CA 92121, USA Representative: CEO Jeff Hamilton
Established: 2018
Business content: Research on hair loss treatment using iPS cells (induced pluripotent stem cells)
Homepage: https://stemsontx.com/
■About Aderans Group
▶Aderans Co., Ltd.’s wig business
Since its founding in 1968, Aderans Co., Ltd. is a total hair solution company that has expanded its business throughout Asia, North America, and Europe.It has 67 companies*1*2 in 19 countries and regions around the world, 448 stores*2 in Japan, We are expanding our business globally with a network of 265 overseas stores*3. In Japan, we have ADERANS, which mainly sells custom-made wigs, and FONTAINE, which sells ready-made wigs, and in North America, we have BOSLEY, which sells hair transplants for men and women. We provide high-quality products and services centered around the hair system “HAIRCLUB” brand.
Aderans’ custom-made wigs use the artificial hair “Cyber Hair,” “Vital Hair,” and “Cyber I am. In addition, at our own factories in Thailand, the Philippines, and Laos, skilled technicians are responsible for producing delicate, high-quality wigs.
*1 Including non-consolidated group companies *2 As of the end of August 2023 *3 As of the end of June 2023
▶ Regarding the development of Bosley’s hair transplant business Bosley is a world leader in hair transplantation, with the top share in the North American market. Bosley hair transplants are performed by highly specialized doctors and medical staff, and involve removing healthy hair follicles (tissue containing hair roots) from the scalp at the back or sides of the head and transplanting them into areas where hair is thinning. We also offer cutting-edge surgical and non-surgical hair restoration solutions, including medical tattoos, PRP (platelet-rich plasma) therapy, and FDA-cleared BosleyRX (telemedicine) solutions. Bosley operates 25 clinics and 50
consultation rooms. (As of the end of May 2023)
Bosley has previously cooperated in ARI research by providing samples of affected areas from patients, and will continue to cooperate with Stemson’s research.
Homepage: https://www.bosley.com/
More details about this release:
https://prtimes.jp/main/html/rd/p/000000864.000010292.html